JP2024514352A5 - - Google Patents
Info
- Publication number
- JP2024514352A5 JP2024514352A5 JP2023564257A JP2023564257A JP2024514352A5 JP 2024514352 A5 JP2024514352 A5 JP 2024514352A5 JP 2023564257 A JP2023564257 A JP 2023564257A JP 2023564257 A JP2023564257 A JP 2023564257A JP 2024514352 A5 JP2024514352 A5 JP 2024514352A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- co2h
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21169757 | 2021-04-21 | ||
| EP21169757.8 | 2021-04-21 | ||
| PCT/IB2022/053698 WO2022224164A1 (en) | 2021-04-21 | 2022-04-20 | Glucagon like peptide compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514352A JP2024514352A (ja) | 2024-04-01 |
| JP2024514352A5 true JP2024514352A5 (enExample) | 2025-04-15 |
Family
ID=75639721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564257A Pending JP2024514352A (ja) | 2021-04-21 | 2022-04-20 | グルカゴン様ペプチド化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240247042A1 (enExample) |
| EP (1) | EP4326330A1 (enExample) |
| JP (1) | JP2024514352A (enExample) |
| KR (1) | KR20230171471A (enExample) |
| CN (1) | CN117202936A (enExample) |
| AR (1) | AR125400A1 (enExample) |
| AU (1) | AU2022260805A1 (enExample) |
| BR (1) | BR112023021597A2 (enExample) |
| CA (1) | CA3216058A1 (enExample) |
| CL (1) | CL2023003091A1 (enExample) |
| IL (1) | IL307822A (enExample) |
| MX (1) | MX2023012290A (enExample) |
| TW (1) | TW202304500A (enExample) |
| WO (1) | WO2022224164A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20221040A1 (es) | 2019-10-25 | 2022-06-17 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| WO2022109182A1 (en) | 2020-11-20 | 2022-05-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| PL4271672T3 (pl) | 2021-04-21 | 2026-04-20 | Gilead Sciences, Inc. | Karboksybenzimidazolowe związki modulujące glp-1r |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| EP3226906B1 (en) * | 2014-11-27 | 2019-06-12 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| CA2972871A1 (en) * | 2015-01-23 | 2016-07-28 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
-
2022
- 2022-04-19 TW TW111114875A patent/TW202304500A/zh unknown
- 2022-04-20 CN CN202280029619.8A patent/CN117202936A/zh active Pending
- 2022-04-20 KR KR1020237039490A patent/KR20230171471A/ko active Pending
- 2022-04-20 MX MX2023012290A patent/MX2023012290A/es unknown
- 2022-04-20 CA CA3216058A patent/CA3216058A1/en active Pending
- 2022-04-20 BR BR112023021597A patent/BR112023021597A2/pt unknown
- 2022-04-20 JP JP2023564257A patent/JP2024514352A/ja active Pending
- 2022-04-20 IL IL307822A patent/IL307822A/en unknown
- 2022-04-20 US US18/556,461 patent/US20240247042A1/en active Pending
- 2022-04-20 AU AU2022260805A patent/AU2022260805A1/en not_active Abandoned
- 2022-04-20 WO PCT/IB2022/053698 patent/WO2022224164A1/en not_active Ceased
- 2022-04-20 EP EP22719363.8A patent/EP4326330A1/en active Pending
- 2022-04-21 AR ARP220101035A patent/AR125400A1/es unknown
-
2023
- 2023-10-17 CL CL2023003091A patent/CL2023003091A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023526973A5 (enExample) | ||
| TWI784914B (zh) | 包含長效胰島素類似物接合物及長效促胰島素肽接合物之治療糖尿病組成物 | |
| US20230126068A1 (en) | Insulin Derivative | |
| EP1330261B1 (en) | Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide | |
| US8598120B2 (en) | Methods for treatment using amylin family peptides | |
| RU2531590C2 (ru) | Аналоги глюкагоноподобного пептида-1 и их применение | |
| US20140206615A1 (en) | Glp-1 agonist and cardiovascular complications | |
| US12139455B2 (en) | Polyethylene glycol derivative and use thereof | |
| JP2012505637A5 (enExample) | ||
| JP2019531320A5 (enExample) | ||
| JP2010031018A5 (enExample) | ||
| TW201305196A (zh) | 包含長效胰島素接合物與長效促胰島素肽接合物之用以治療糖尿病之組成物 | |
| JP2014504597A (ja) | アシル化グルカゴン類似体とインスリン類似体の組合せ物 | |
| HK1225307A1 (en) | Engineered polypeptides having enhanced duration of action | |
| JP2001011095A (ja) | Ｇｌｐ−１誘導体 | |
| JP2023545684A5 (enExample) | ||
| JP2009286804A5 (enExample) | ||
| JP2021522258A5 (enExample) | ||
| WO2020185533A1 (en) | Growth differentiation factor 15 combination therapy | |
| JP2025525218A (ja) | インクレチンアナログおよびその使用 | |
| TW202308620A (zh) | 包括ｇｐｒ４０促進劑以及ｓｇｌｔ－２抑制物之醫藥組成物及其製備方法 | |
| JP2023553561A5 (enExample) | ||
| JP2023533413A (ja) | 長時間作用型ｇｌｐ－１およびグルカゴン受容体デュアルアゴニスト | |
| JP2024527220A5 (enExample) | ||
| HK40128194A (zh) | 一种glp1/gdf15双重激动剂 |